MarketCap
Greenwich LifeSciences GLSI
$ 16.05
-2.85%
Facebook
X
Telegram
Greenwich LifeSciences ROCE Ratio | GLSI
Annual ROCE Ratio Greenwich LifeSciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5505.94 | -1941.09 | -139.21 | -60.85 | -17.14 | -6745.27 | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -17.14 | -6745.27 | -2401.58 |
Quarterly ROCE Ratio Greenwich LifeSciences
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1191.68 | -1026.97 | -722.25 | -777.02 | -631.25 | -399.73 | -149.61 | -177.89 | -139.53 | -113.41 | -63.87 | -79.33 | -55.61 | -49.4 | -30.22 | -33.26 | -20.38 | -17.84 | -7.65 | -8.58 | -6.29 | -4.6 | -2.58 | 22.31 | -0.76 | -0.89 | - | 24.88 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 24.88 | -1191.68 | -209.76 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Repare Therapeutics
RPTX
|
-61.88 | - | - | $ 112 M |  Canada |
 |
Sesen Bio
SESN
|
222.79 | - | 7.29 % | $ 127 M |  USA |
 |
Windtree Therapeutics
WINT
|
-261.49 | - | - | $ 26.8 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
-141.18 | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
-159.95 | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
-129.64 | - | - | $ 13 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Lyra Therapeutics
LYRA
|
289.47 | - | - | $ 24.9 M | USA |
 |
Brickell Biotech
BBI
|
-64.05 | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
-175.6 | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
-29.63 | - | - | $ 8.86 M | Canada |
 |
Generation Bio Co.
GBIO
|
-165.18 | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
74.33 | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
-41.99 | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
-71.67 | - | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
-92.11 | $ 4.2 | -0.71 % | $ 651 M | USA |
 |
AbbVie
ABBV
|
-461.01 | $ 293.87 | 0.19 % | $ 520 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
14.33 | $ 151.6 | -3.2 % | $ 19.9 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-68.09 | $ 4.63 | 21.05 % | $ 20 M |  Israel |
 |
Avenue Therapeutics
ATXI
|
-168.29 | - | -52.27 % | $ 4.45 M | USA |
 |
Axon Enterprise
AXON
|
-1.91 | $ 302.6 | -0.19 % | $ 23.6 B | USA |
 |
Theratechnologies
THTX
|
49.6 | - | - | $ 83.9 M | Canada |
 |
Liquidia Corporation
LQDA
|
-26.74 | $ 51.37 | 7.31 % | $ 4.42 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-31.41 | $ 45.05 | -9.97 % | $ 4.05 B |  Schweiz |
 |
Scholar Rock Holding Corporation
SRRK
|
-110.26 | $ 48.48 | -5.96 % | $ 5.56 B | USA |
 |
Geron Corporation
GERN
|
-14.94 | $ 0.96 | -3.71 % | $ 640 M | USA |
 |
Bristol-Myers Squibb Company
BMY
|
5.3 | $ 62.8 | 1.06 % | $ 128 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
-186.76 | - | -3.76 % | $ 3.47 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-45.76 | $ 7.4 | -0.13 % | $ 113 M |  Australia |
 |
Celldex Therapeutics
CLDX
|
-54.02 | $ 30.68 | -1.81 % | $ 2.04 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-141.54 | $ 4.0 | -6.76 % | $ 48.8 M | Israel |
 |
Allena Pharmaceuticals
ALNA
|
-53.64 | - | 3.16 % | $ 1.9 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
2.69 | $ 317.26 | 0.99 % | $ 6.14 B | USA |
 |
Eli Lilly and Company
LLY
|
21.04 | $ 1 432.7 | 1.47 % | $ 1.29 T | USA |
 |
TCR2 Therapeutics
TCRR
|
-108.97 | - | - | $ 58.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-52.09 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
|
TFF Pharmaceuticals
TFFP
|
-228.86 | - | -60.05 % | $ 125 K | USA |
 |
Mesoblast Limited
MESO
|
-13.2 | $ 14.0 | -3.06 % | $ 16.9 B | Australia |
 |
CorMedix
CRMD
|
37.04 | $ 5.37 | -2.1 % | $ 387 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-580.3 | - | -15.15 % | $ 60.3 M |  Britain |
 |
MannKind Corporation
MNKD
|
6.25 | $ 4.22 | 0.84 % | $ 1.29 B | USA |
 |
AVEO Pharmaceuticals
AVEO
|
-13.43 | - | - | $ 521 M | USA |
 |
MediciNova
MNOV
|
-31.94 | $ 1.4 | -4.76 % | $ 68.7 M | USA |
 |
Merck & Co.
MRK
|
19.69 | $ 147.75 | -0.68 % | $ 370 B | USA |
 |
Moderna
MRNA
|
-29.7 | $ 250.79 | -6.77 % | $ 97.6 B | USA |
 |
Axcella Health
AXLA
|
-1848.9 | - | -16.42 % | $ 249 M | USA |